{
    "clinical_study": {
        "@rank": "18151", 
        "arm_group": [
            {
                "arm_group_label": "2% NVN1000 Topical Gel", 
                "arm_group_type": "Experimental", 
                "description": "2% NVN1000 Topical Gel once daily for 4 weeks"
            }, 
            {
                "arm_group_label": "4% NVN1000 Topical Gel", 
                "arm_group_type": "Experimental", 
                "description": "4% NVN1000 4% Topical Gel once daily for 4 weeks"
            }, 
            {
                "arm_group_label": "Vehicle Topical Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle Topical Gel once daily for 4 weeks"
            }, 
            {
                "arm_group_label": "8% NVN1000 Topical Gel", 
                "arm_group_type": "Experimental", 
                "description": "8% NVN1000 8% Topical Gel applied once daily for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess safety and tolerability of different doses of topical gel containing a\n      new chemical entity, NVN1000, and the vehicle (gel without drug)  applied to the face of\n      healthy volunteers with high counts of Propionibacterium acnes.  The test product will be\n      applied once daily for 4 weeks.  Exploratory measures include whether the topical product\n      decreases the amount of a bacteria associated with acne (P. acnes)."
        }, 
        "brief_title": "Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "This is a single center, observer blinded, randomized, multiple dose study with 3 doses of\n      NVN1000 and vehicle applied once daily for 4 weeks.  There are 4 arms to the study (3 active\n      and 1 vehicle)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers\n\n          -  Age 18 or older\n\n          -  High degree of fluorescence of facial skin under Wood's lamp\n\n        Exclusion Criteria:\n\n          -  Acute or chronic skin disorders\n\n          -  Use of topical or systemic antibiotics within 4 weeks of study\n\n          -  Concomitant use of nitroglycerin or other nitric oxide donor drugs\n\n          -  Females who are pregnant, planning pregnancy or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694810", 
            "org_study_id": "NI-AC002"
        }, 
        "intervention": [
            {
                "arm_group_label": "2% NVN1000 Topical Gel", 
                "description": "2% NVN1000 Topical Gel once daily for 4 weeks", 
                "intervention_name": "2% NVN1000 Topical Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4% NVN1000 Topical Gel", 
                "description": "4% NVN 1000 4% Topical Gel applied once daily 4 weeks", 
                "intervention_name": "4% NVN1000 Topical Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "8% NVN1000 Topical Gel", 
                "description": "8% NVN1000 Topical Gel applied once daily for 4 weeks", 
                "intervention_name": "8% NVN1000 Topical Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle Topical Gel", 
                "description": "Vehicle Topical Gel applied once daily", 
                "intervention_name": "Vehicle Topical Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "acne vulgaris", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Broomall", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19008"
                }, 
                "name": "KGL, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1 Multiple Dose, Single-Center, Observer-Blind Parallel Group Study Evaluating Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers", 
        "other_outcome": {
            "description": "P. Acnes counts", 
            "measure": "Change in Microbiology", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4 weeks"
        }, 
        "overall_official": {
            "affiliation": "KGL, Inc.", 
            "last_name": "James J Leyden, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cutaneous tolerability using a 4 point (0-3) assessment tool", 
            "measure": "Cutaneous Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety assessments include physical examinations with vital signs, laboratory testing", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "source": "Novan, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novan, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}